NAFLD and NASH are obesity-independent risk factors in COVID-19: Matched real-world results from the large PINC AI™ Healthcare Database.
COVID-19
MASH
MASLD
NAFLD
NASH
SARS-CoV-2
chronic liver disease
fatty liver
metabolic syndrome
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
18 Dec 2023
18 Dec 2023
Historique:
revised:
09
11
2023
received:
22
02
2023
accepted:
25
11
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are potential risk factors for severe pneumonia and other infections. Available data on the role of NAFLD/NASH in worsening outcomes for COVID-19 are controversial and might be confounded by comorbidities. We used the PINC AI™ Healthcare Data Special Release (PHD-SR) to identify patients with COVID-19 (ICD-10) at approximately 900 hospitals in the United States. We performed exact matching (age, gender, and ethnicity) for patients with or without NAFLD/NASH, adjusting for demographics (admission type, region) and comorbidities (e.g., obesity, diabetes) through inverse probability of treatment weighting and then analysed hospitalisation-related outcomes. Among 513 623 patients with SARS-CoV-2 (COVID-19), we identified 14 667 with NAFLD/NASH who could be matched to 14 667 controls. Mean age was 57.6 (±14.9) years, 50.8% were females and 43.7% were non-Hispanic whites. After matching, baseline characteristics (e.g., age, ethnicity, and gender) and comorbidities (e.g., hypertension, obesity, diabetes, and cardiovascular disease) were well balanced (standard difference (SD) <.10), except for cirrhosis and malignancies. Patients with COVID-19 and NAFLD/NASH had higher FIB-4 scores, a significantly longer hospital length of stay (LOS) and intensive care LOS than controls (9.4 vs. 8.3 days, and 10.4 vs. 9.3, respectively), even after adjusting for cirrhosis and malignancies. Patients with COVID-19 and NAFLD/NASH also had significantly higher risk of needing invasive mandatory ventilation (IMV) (odds ratio 1.0727; 95% CI 1.0095-1.1400). Other outcomes were similar in both groups. In this large real-world cohort of patients hospitalised for COVID-19 in the United States, NAFLD/NASH were obesity-independent risk factors for complicated disease courses.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are potential risk factors for severe pneumonia and other infections. Available data on the role of NAFLD/NASH in worsening outcomes for COVID-19 are controversial and might be confounded by comorbidities.
METHODS
METHODS
We used the PINC AI™ Healthcare Data Special Release (PHD-SR) to identify patients with COVID-19 (ICD-10) at approximately 900 hospitals in the United States. We performed exact matching (age, gender, and ethnicity) for patients with or without NAFLD/NASH, adjusting for demographics (admission type, region) and comorbidities (e.g., obesity, diabetes) through inverse probability of treatment weighting and then analysed hospitalisation-related outcomes.
RESULTS
RESULTS
Among 513 623 patients with SARS-CoV-2 (COVID-19), we identified 14 667 with NAFLD/NASH who could be matched to 14 667 controls. Mean age was 57.6 (±14.9) years, 50.8% were females and 43.7% were non-Hispanic whites. After matching, baseline characteristics (e.g., age, ethnicity, and gender) and comorbidities (e.g., hypertension, obesity, diabetes, and cardiovascular disease) were well balanced (standard difference (SD) <.10), except for cirrhosis and malignancies. Patients with COVID-19 and NAFLD/NASH had higher FIB-4 scores, a significantly longer hospital length of stay (LOS) and intensive care LOS than controls (9.4 vs. 8.3 days, and 10.4 vs. 9.3, respectively), even after adjusting for cirrhosis and malignancies. Patients with COVID-19 and NAFLD/NASH also had significantly higher risk of needing invasive mandatory ventilation (IMV) (odds ratio 1.0727; 95% CI 1.0095-1.1400). Other outcomes were similar in both groups.
CONCLUSIONS
CONCLUSIONS
In this large real-world cohort of patients hospitalised for COVID-19 in the United States, NAFLD/NASH were obesity-independent risk factors for complicated disease courses.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
World Health Organisation. WHO Coronavirus (COVID-19) Dashboard. 2023. Accessed May 25, 2022. covid19.who.int
Hodcroft E. CoVariants. 2022. Accessed November 20, 2022. https://covariants.org
Goyal P, Ringel JB, Rajan M, et al. Obesity and COVID-19 in New York City: a retrospective cohort study. Ann Intern Med. 2020;173(10):855-858. doi:10.7326/M20-2730
Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-436. doi:10.1038/s41586-020-2521-4
Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. doi:10.1016/j.jhep.2023.06.003
Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72(5):1605-1616. doi:10.1002/hep.31173
Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6):2672-2682. doi:10.1002/hep.30251
Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547-555. doi:10.1053/j.gastro.2014.11.039
Younossi ZM, Stepanova M, Ong J, et al. Nonalcoholic steatohepatitis is the Most rapidly increasing indication for liver transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19(3):580-589 e5. doi:10.1016/j.cgh.2020.05.064
Kovalic AJ, Satapathy SK, Thuluvath PJ. Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis. Hepatol Int. 2020;14(5):612-620. doi:10.1007/s12072-020-10078-2
Hegyi PJ, Vancsa S, Ocskay K, et al. Metabolic associated fatty liver disease is associated with an increased risk of severe COVID-19: a systematic review with meta-analysis. Front Med (Lausanne). 2021;8:626425. doi:10.3389/fmed.2021.626425
Belli LS, Duvoux C, Cortesi PA, et al. COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes-an ELITA/ELTR multicentre cohort study. Gut. 2021;70(10):1914-1924. doi:10.1136/gutjnl-2021-324879
Mahamid M, Nseir W, Khoury T, et al. Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study. Eur J Gastroenterol Hepatol. 2021;33(12):1578-1581. doi:10.1097/MEG.0000000000001902
Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74(3):567-577. doi:10.1016/j.jhep.2020.09.024
Brozat JF, Hanses F, Haelberger M, et al. COVID-19 mortality in cirrhosis is determined by cirrhosis-associated comorbidities and extrahepatic organ failure: results from the multinational LEOSS registry. United European Gastroenterol J. 2022;10(4):409-424. doi:10.1002/ueg2.12232
Bramante C, Tignanelli CJ, Dutta N, et al. Non-alcoholic fatty liver disease (NAFLD) and risk of hospitalization for COVID-19. medRxiv. 2020. doi:10.1101/2020.09.01.20185850
Hashemi N, Viveiros K, Redd WD, et al. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience. Liver Int. 2020;40(10):2515-2521. doi:10.1111/liv.14583
Ji D, Qin E, Xu J, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;73(2):451-453. doi:10.1016/j.jhep.2020.03.044
Wang Y, Wang Y, Duan G, Yang H. NAFLD was independently associated with severe COVID-19 among younger patients rather than older patients: a meta-analysis. J Hepatol. 2022;78:e136-e139. doi:10.1016/j.jhep.2022.10.009
Abolfazli P, Aghajanzadeh T, Ghaderinasrabad M, Apue Nchama CN, Mokhlesi A, Talkhabi M. Bioinformatics analysis reveals molecular connections between non-alcoholic fatty liver disease (NAFLD) and COVID-19. J Cell Commun Signal. 2022;16(4):609-619. doi:10.1007/s12079-022-00678-y
Hayat U, Ashfaq MZ, Johnson L, et al. The Association of Metabolic-Associated Fatty Liver Disease with clinical outcomes of COVID-19: a systematic review and meta-analysis. Kans J Med. 2022;15:241-246. doi:10.17161/kjm.vol15.16522
Chang Y, Jeon J, Song TJ, Kim J. Association between the fatty liver index and the risk of severe complications in COVID-19 patients: a nationwide retrospective cohort study. BMC Infect Dis. 2022;22(1):384. doi:10.1186/s12879-022-07370-x
Moctezuma-Velazquez P, Miranda-Zazueta G, Ortiz-Brizuela E, et al. NAFLD determined by Dallas steatosis index is associated with poor outcomes in COVID-19 pneumonia: a cohort study. Intern Emerg Med. 2022;17(5):1355-1362. doi:10.1007/s11739-022-02933-x
Zhang J, Liu F, Song T, et al. Liver fibrosis scores and clinical outcomes in patients with COVID-19. Front Med (Lausanne). 2022;9:829423. doi:10.3389/fmed.2022.829423
Liu M, Mei K, Tan Z, et al. Liver fibrosis scores and hospitalization, mechanical ventilation, severity, and death in patients with COVID-19: a systematic review and dose-response meta-analysis. Can J Gastroenterol Hepatol. 2022;2022:7235860. doi:10.1155/2022/7235860
Li J, Tian A, Zhu H, et al. Mendelian randomization analysis reveals No causal relationship between nonalcoholic fatty liver disease and severe COVID-19. Clin Gastroenterol Hepatol. 2022;20(7):1553-1560 e78. doi:10.1016/j.cgh.2022.01.045
Liu D, Zhang Q, Bai P, Zhao J. Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease. J Hepatol. 2022;76(3):740-742. doi:10.1016/j.jhep.2021.11.014
Mushtaq K, Khan MU, Iqbal F, et al. NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression-the debate continues. J Hepatol. 2021;74(2):482-484. doi:10.1016/j.jhep.2020.09.006
Ji D, Cheng G, Lau G. Reply to: “NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression-the debate continues”. J Hepatol. 2021;74(2):484-485. doi:10.1016/j.jhep.2020.10.020
Yoo HW, Shin JI, Yon DK, Lee SW. COVID-19 morbidity and severity in patients with nonalcoholic fatty liver disease in South Korea: a Nationwide cohort study. Clin Gastroenterol Hepatol. 2022;20(5):e1217-e1218. doi:10.1016/j.cgh.2021.07.031
Nseir WB, Mograbi JM, Amara AE, Abu Elheja OH, Mahamid MN. Non-alcoholic fatty liver disease and 30-day all-cause mortality in adult patients with community-acquired pneumonia. QJM. 2019;112(2):95-99. doi:10.1093/qjmed/hcy227
Lee CH, Choi SH, Chung GE, Park B, Kwak MS. Nonalcoholic fatty liver disease is associated with decreased lung function. Liver Int. 2018;38(11):2091-2100. doi:10.1111/liv.13860
Marjot T, Eberhardt CS, Boettler T, et al. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper. J Hepatol. 2022;77(4):1161-1197. doi:10.1016/j.jhep.2022.07.008
United States Census Bureau. Population and Housing Unit Estimates Datasets. Accessed November 19, 2022. census.gov/programs-surveys/popest/data/data-sets.2016.html
von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-1457. doi:10.1016/S0140-6736(07)61602-X
United States Census Bureau. Accessed November 20, 2022. census.gov/library/visualisations/interactive/race-and-ethnicity-in-the-united-state-2010-and-2020-census.html
Adams ML, Katz DL, Grandpre J. Population-based estimates of chronic conditions affecting risk for complications from coronavirus disease, United States. Emerg Infect Dis. 2020;26(8):1831-1833. doi:10.3201/eid2608.200679
Schmitz SM, Kroh A, Ulmer TF, et al. Evaluation of NAFLD and fibrosis in obese patients-a comparison of histological and clinical scoring systems. BMC Gastroenterol. 2020;20(1):254. doi:10.1186/s12876-020-01400-1
Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657-1669. doi:10.1053/j.gastro.2021.07.049
Tacke F, Roeb E, Canbay A. Die wichtigsten Neuerungen in der aktualisierten S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft fur Gastroenterologie, Verdauungs-und Stoffwechselkrankheiten (DGVS). Z Gastroenterol. 2022;60(9):1303-1305. doi:10.1055/a-1899-9046
Canbay A, Kachru N, Haas JS, Meise D, Ozbay AB, Sowa JP. Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. Ann Transl Med. 2021;9(8):615. doi:10.21037/atm-20-7179
Puengel T, Tacke F. Editorial: prevalence, progression rates and mortality predictors of non-alcoholic fatty liver disease reflected by German statutory health insurance data. Aliment Pharmacol Ther. 2020;52(8):1412-1413. doi:10.1111/apt.16077
Hayward KL, Johnson AL, Horsfall LU, Moser C, Valery PC, Powell EE. Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM. BMJ Open Gastroenterol. 2021;8(1):e000572. doi:10.1136/bmjgast-2020-000572
Corey KE, Kartoun U, Zheng H, Shaw SY. Development and validation of an algorithm to identify nonalcoholic fatty liver disease in the electronic medical record. Dig Dis Sci. 2016;61(3):913-919. doi:10.1007/s10620-015-3952-x
Lombardi R, Mura V, Cespiati A, et al. Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity. Intern Emerg Med. 2022;17(6):1739-1749. doi:10.1007/s11739-022-03000-1
Targher G, Mantovani A, Byrne CD, et al. Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020;69(8):1545-1547. doi:10.1136/gutjnl-2020-321611
Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60-78. doi:10.1038/s41575-021-00523-4
Shang Y, Widman L, Ebrahimi F, Ludvigsson JF, Hagstrom H, Wester A. Risk of infections in non-alcoholic fatty liver disease: a nationwide population-based cohort study. Liver Int. 2023;43(10):2142-2152. doi:10.1111/liv.15680
Gao X, Lv F, He X, et al. Impact of the COVID-19 pandemic on liver disease-related mortality rates in the United States. J Hepatol. 2023;78(1):16-27. doi:10.1016/j.jhep.2022.07.028